


The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement, for which the directors (the “**Directors**”) of Sino Biopharmaceutical Limited (the “**Company**”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise market (“**GEM**”) of the Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading; there are no other matters the omission of which would make any statement in this announcement misleading; and all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liabilities)

RESULTS OF THE EXTRAORDINARY GENERAL MEETING RELATING TO THE RESOLUTION ON THE ADOPTION OF A NEW SHARE OPTION SCHEME AND TERMINATION OF THE EXISTING SHARE OPTION SCHEME

At the Extraordinary General Meeting, the resolution relating to the adoption of the New Scheme and the termination of the Existing Scheme was duly passed by the Shareholders.

Reference is made to the circular of the Company dated 10 April, 2002 issued to the shareholders of the Company (“**Shareholders**”) which contained a notice of the extraordinary general meeting of the Company convened to be held on 26 April, 2002 (“**Extraordinary General Meeting**”) to consider and, if thought fit, pass the resolution relating to the adoption of a new share option scheme of the Company (“**New Scheme**”) and the termination of the existing share option scheme of the Company (“**Existing Scheme**”).

The Directors are pleased to announce that the above resolution was duly passed by the Shareholders at the Extraordinary General Meeting.

On behalf of the Board
Tse Ping
Chairman

Hong Kong, 26 April, 2002

This announcement will remain on the GEM website at www.hkgem.com on the “Latest Company Announcements” page for at least seven days from the date of its posting and on the website of Sino Biopharmaceutical Limited at www.sinobiopharm.com.